Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
June 16, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
May 05, 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Pernix Prescriptions DirectTM Achieves Increased Penetration MORRISTOWN, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a...
Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016
April 28, 2016 08:30 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that it will release financial results for...
Pernix Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference
April 05, 2016 16:01 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., April 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief...
Pernix Therapeutics Files Citizen Petition Following Issuance of U.S. Patent Number 9,265,760 (‘760 Patent) Covering Safety Information Related to Dosing Patients with Zohydro ER® with BeadTek™ CII
March 02, 2016 08:30 ET
|
Pernix Therapeutics Holdings, Inc.
Morristown, NJ, March 02, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced their submission of a Citizen Petition to...
Pernix Therapeutics to Report Fourth Quarter and Full-Year 2015 Financial Results on Thursday, March 10, 2016
February 24, 2016 08:43 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that it will release its fourth quarter and...
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
November 12, 2015 11:15 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV...
USACE, Far East District AP Selects Pernix-Kaseman JV for Construction Project in South Korea
February 27, 2015 14:15 ET
|
Michael Baker International
MCLEAN, Va., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Kaseman, a Michael Baker International company, announced that the U.S. Army Corps of Engineers (USACE), Far East District AP has awarded the...
Pamlab LLC and Others Seek U.S. International Trade Commission Action to Block Importation of Certain Medical Food Products and Ingredients
September 12, 2012 11:49 ET
|
Pamlab LLC
WASHINGTON, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Pamlab LLC, a specialty pharmaceutical company that provides medical foods and foods for special dietary use, has joined Merck & Cie and South...